GSK has crossed the finish line with Arexvy (RSVPreF3-AS01E), the first respiratory syncytial virus (RSV) vaccine to win FDA approval for individuals age 60 years and older, but approval of Pfizer’s RSV candidate, Abrysvo (RSVpreF), may not be far behind.
Source: Drug Industry Daily